Skip to main content
REGN
NASDAQ Life Sciences

Regeneron Hits 52-Week High as Q3 EPS Tops Consensus by 24%

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$910.52
Mkt Cap
$93.743B
52W Low
$591.52
52W High
$935.35
52W Position info
54% above low
Off High info
2.7% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

REGN sits 54% above its 52-week low of $591.52 on elevated volume (2.3× avg).

Summary

Regeneron's Q3 adjusted EPS of $20.07 came in well above the $16.19 consensus, and revenue of $5.116 billion beat the $4.542 billion estimate on record Dupixent, Eylea HD and Libtayo sales. Shares jumped 11.46% to $912.63, a new 52-week high. Eylea HD US net sales rose 62% to a record $699 million and now make up nearly two-thirds of the US retinal franchise; Libtayo global sales climbed 51% in constant currency to $550 million. The beat was helped by higher Sanofi collaboration revenue after the Q2 repayment of the development balance, which lets Regeneron recognize its full share of collaboration profits — the same Sanofi pact expanded on October 1. Management guided Q4 Eylea HD physician unit demand up about 10% sequentially and full-year Eylea HD net sales up more than 50%, while flagging a low-to-mid-teens sequential decline in older Eylea demand and rising aflibercept biosimilar competition. A potential FDA approval of the Eylea HD prefilled syringe is the next item that could support 2027 growth.

At the time of this announcement, REGN was trading at $910.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.7B. The 52-week trading range was $591.52 to $935.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $950.03 info
Change: +$50.03 (+6%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $950.03 info
Change: +$94.03 (+11%) info
Market Cap: $98.825B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $950.03 info
Change: +$115.03 (+14%) info
Market Cap: $98.825B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $950.03 info
Change: +$185.58 (+24%) info
Market Cap: $98.825B info
REGN
Oct 06, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $721.96
Real-time Price: $950.03 info
Change: +$228.07 (+32%) info
Market Cap: $98.825B info